Tvardi Therapeutics, Inc. (TVRD) - Net Assets
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has net assets worth $14.51 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.82 Million) and total liabilities ($11.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tvardi Therapeutics, Inc. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.51 Million |
| % of Total Assets | 56.18% |
| Annual Growth Rate | -39.05% |
| 5-Year Change | -90.79% |
| 10-Year Change | N/A |
| Growth Volatility | 55.59 |
Tvardi Therapeutics, Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Tvardi Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. See Tvardi Therapeutics, Inc. (TVRD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual net assets of Tvardi Therapeutics, Inc. from 2020 to 2025. For live valuation and market cap data, see TVRD market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $20.95 Million | +556.04% |
| 2024-12-31 | $-4.59 Million | +92.60% |
| 2023-12-31 | $-62.06 Million | -37.75% |
| 2022-12-31 | $-45.05 Million | -119.80% |
| 2021-12-31 | $227.52 Million | -8.63% |
| 2020-12-31 | $249.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tvardi Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 28186700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.04% |
| Other Comprehensive Income | $8.00K | 0.04% |
| Other Components | $131.38 Million | 627.23% |
| Total Equity | $20.95 Million | 100.00% |
Tvardi Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lamor Corporation Oyj
HE:LAMOR
|
$24.21 Million |
|
Omnisystem Co.Ltd
KQ:057540
|
$24.22 Million |
|
Environmental Group Ltd (the)
AU:EGL
|
$24.23 Million |
|
Hitechpros
PA:ALHIT
|
$24.23 Million |
|
Zeo Energy Corp.
NASDAQ:ZEO
|
$24.19 Million |
|
Uni Chem
KO:011330
|
$24.19 Million |
|
Helium Evolution Inc
V:HEVI
|
$24.17 Million |
|
SCGM Bhd
KLSE:7247
|
$24.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tvardi Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -4,593,000 to 20,946,000, a change of 25,539,000.
- Net loss of 18,214,000 reduced equity.
- New share issuances of 532,000 increased equity.
- Other comprehensive income increased equity by 8,000.
- Other factors increased equity by 43,213,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.21 Million | -86.96% |
| Share Issuances | $532.00K | +2.54% |
| Other Comprehensive Income | $8.00K | +0.04% |
| Other Changes | $43.21 Million | +206.31% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Tvardi Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.96x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $187.08 | $2.58 | x |
| 2021-12-31 | $161.49 | $2.58 | x |
| 2022-12-31 | $-4.82 | $2.58 | x |
| 2023-12-31 | $-6.63 | $2.58 | x |
| 2024-12-31 | $-3.02 | $2.58 | x |
| 2025-12-31 | $2.69 | $2.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tvardi Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.53x
- Recent ROE (-86.96%) is below the historical average (-20.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 3.38% | 6.23% | 0.50x | 1.09x | $-16.49 Million |
| 2021 | -38.87% | -384.06% | 0.09x | 1.09x | $-111.19 Million |
| 2022 | 0.00% | -204.16% | 0.93x | 0.00x | $-80.97 Million |
| 2023 | 0.00% | -565.21% | 0.78x | 0.00x | $-112.31 Million |
| 2024 | 0.00% | -992.95% | 0.16x | 0.00x | $-70.41 Million |
| 2025 | -86.96% | 0.00% | 0.00x | 1.53x | $-20.31 Million |
Industry Comparison
This section compares Tvardi Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $14.51 Million | 3.38% | 0.78x | $24.20 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more